Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report)’s stock price traded down 6.3% on Tuesday . The company traded as low as $20.13 and last traded at $20.16. 341,502 shares were traded during trading, a decline of 56% from the average session volume of 776,676 shares. The stock had previously closed at $21.52.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $124.00 price objective on shares of Cassava Sciences in a report on Tuesday, March 5th.
Read Our Latest Analysis on SAVA
Cassava Sciences Stock Performance
Cassava Sciences (NASDAQ:SAVA – Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). Sell-side analysts predict that Cassava Sciences, Inc. will post -2.01 earnings per share for the current year.
Institutional Trading of Cassava Sciences
Large investors have recently modified their holdings of the company. Montag A & Associates Inc. grew its position in Cassava Sciences by 50.0% in the 3rd quarter. Montag A & Associates Inc. now owns 1,500 shares of the company’s stock valued at $25,000 after buying an additional 500 shares in the last quarter. Northwest Financial Advisors bought a new position in Cassava Sciences in the 4th quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. grew its position in Cassava Sciences by 653.6% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,153 shares of the company’s stock valued at $26,000 after buying an additional 1,000 shares in the last quarter. Headlands Technologies LLC grew its position in Cassava Sciences by 24,044.4% in the 3rd quarter. Headlands Technologies LLC now owns 2,173 shares of the company’s stock valued at $36,000 after buying an additional 2,164 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Cassava Sciences in the 3rd quarter valued at about $66,000. Institutional investors and hedge funds own 38.05% of the company’s stock.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Cassava Sciences
- Stock Splits, Do They Really Impact Investors?
- Garmin Navigates to New Highs Driven By Wearables Trend
- Consumer Staples Stocks, Explained
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What Are Dividends? Buy the Best Dividend Stocks
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.